Locally delivered EGFR/IL13Rα2 CAR T-cell therapy for recurrent high-grade gliomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, dose-finding trial uses autologous T cells engineered with CARs against EGFR and IL13Rα2 that are administered locoregionally via a thin flexible catheter placed into the brain. The primary goal is to define safety and the maximum tolerated dose, while secondary endpoints include disease control rate, response rates, time to progression, and 12-month overall survival among patients who receive planned doses. Participants undergo leukapheresis to collect T cells, manufacturing of the dual-targeted CAR T product, and one or more intracranial infusions with serial clinical and imaging monitoring. Exploratory analyses will measure cytokines and immune and tumor microenvironment markers in CSF, tumor cavity fluid, and blood and relate them to adverse events and outcomes.

Why it matters

Who can join: the full rules

Main Inclusion Criteria

* Documented informed consent of the participant and/or legally authorized representative.
* Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with Study PI approval.
* Age 18 years and older.
* KPS ≥ 70%, ECOG ≤ 2 (Appendix A).
* Life expectancy ≥ 4 weeks.
* Participant has a prior histologically confirmed diagnosis of a glioblastoma (IDH-wildtype) or grade 4 IDH-mutant astrocytoma, or has a prior histologically confirmed diagnosis of a grade 2 or 3 astrocytoma and now has radiographic progression consistent with grade 4 IDH-mutant astrocytoma.
* Relapsed disease: radiographic evidence of recurrence/progression of measurable disease after standard therapy (such as temozolomide with or without Optune device), and ≥ 12 weeks after completion of front-line radiation therapy.
* COH Clinical Pathology assessment at the initial tumor presentation or recurrent disease (reference Appendix B):

  * IL13Rα2+ expression by IHC \> 20, and
  * EGFR gene-altered by NGS or FISH analysis
* No known contraindications to leukapheresis, steroids, imaging studies, or tocilizumab.
* WBC \> 2000 /dl (or ANC ≥ 1,000/mm3)
* Platelets ≥ 75,000/mm3
* Hemoglobin \> 9g/dL
* Total bilirubin ≤ 1.5x ULN
* AST ≤ 2.5x ULN
* ALT ≤ 2.5x ULN
* Serum creatinine ≤1.6 mg/dL
* O2 saturation ≥ 95% on room air.
* Seronegative for HIV Ag/Ab combo, HCV, and active HBV
* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test.
* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of CAR T cells.

Main Exclusion Criteria

* Owing to higher frequency of wound-related complications, participants who require active bevacizumab therapy at the time of enrollment are excluded.
* Participant has not yet recovered from toxicities of prior therapy.
* Participant has received any live vaccine within 30 days prior to enrollment.
* Uncontrolled seizure activity and/or clinically evident progressive encephalopathy.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
* Clinically significant uncontrolled illness.
* Active autoimmune disease requiring systemic immunosuppressive therapy
* Active infection requiring IV antibiotics (for example, minor scalp infection is not exclusion).
* Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection.
* Other active malignancy.
* Females only: Pregnant or breastfeeding.
* Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures.
* Prospective participants who, in the opinion of the Investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

Where it's running

• City of Hope Medical Center
  Duarte, California, United States Recruiting

Study contacts

• Principal investigator: Behnam Badie — City of Hope Medical Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• GI-102 With or Without Pembrolizumab Before Surgery for Recurrent or Progressive Grade 4 Gliomas

  The team will test whether giving GI-102 alone or together with pembrolizumab before surgery helps adults with recurrent or progressive IDH‑wildtype glioblastoma or IDH‑mutant grade 4 astrocytoma.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07301268

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

• Adding triapine to radiation therapy for recurrent glioblastoma and astrocytoma

  This early-phase study tests whether giving the drug triapine together with radiation is safe and tolerable for adults whose glioblastoma or astrocytoma has come back.

  Recruiting at 36 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 42 other locations · NCT06860594

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.